Alzheimer's Disease Trial, Recruiting NCT04956549 Sponsor: Pennington Biomedical Research Center Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT04956549
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who identify as African American
  • People aged 60 or older
  • People who are physically able to exercise
  • People who have not been regularly physically active
  • People who score at or above a certain level on a standard physical performance test (a score of 4 or higher on a test called the Short Physical Performance Battery)
  • People whose thinking and memory scores fall slightly below the normal range for their age and sex on a standard cognitive test — this is consistent with a condition called mild cognitive impairment (MCI) (confirm with trial site)
  • People who are not able to use certain devices or apps on their own for the study (confirm with trial site)
  • People who are willing to attend group sessions
  • People who plan to stay in the study area for the next 13 months and are able to travel to the study location for visits and sessions
  • People who do not have conditions that would make regular exercise unsafe, as assessed by the trial's medical investigator
  • People who are willing to allow researchers to use their data for research purposes after the study ends
  • People who are willing to be randomly assigned to a study group

Who may not be able to join:

  • People whose cognitive test scores fall into the range associated with dementia (confirm with trial site)
  • People who have been diagnosed with dementia
  • People who are unwilling to provide written consent or to be randomly assigned to a study group
  • People who are already too physically active — specifically, those whose recorded moderate-to-vigorous physical activity over a 7-day period meets certain thresholds (confirm with trial site for exact activity levels)
  • People with uncontrolled high blood pressure (blood pressure above certain levels, specifically systolic above 150 or diastolic above 90)
  • People who have had a heart attack, major heart surgery, stroke, a blood clot in a vein or lung, a broken hip, hip or knee replacement, or spinal surgery within the past 6 months
  • People currently taking part in cardiac or pulmonary rehabilitation
  • People with uncontrolled diabetes that the medical investigator believes may interfere with participation
  • People with a diagnosed bone-thinning condition (osteoporosis) that the medical investigator believes may interfere with participation
  • People currently enrolled in another randomised trial involving lifestyle or medication changes
  • People who live in the same household as another participant in this trial or a related trial called RAATE or RAATE MCI
  • People who refuse to participate unless they are told their amyloid PET scan results (a specific brain scan result related to the study)
  • People who refuse to allow anonymised versions of their study data to be used for future research
  • People with other medical, psychiatric, or behavioural factors that the principal or medical investigator believes may interfere with participation or following the study program

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Robert L Newton, Jr., PhD, Pennington Biomedical Research

Phone: 225-763-2362

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Pennington Biomedical Research Center
Registry
ClinicalTrials.gov
Start date
1 June 2021
Est. completion
31 March 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in executive function; Change in episodic memory

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov